NGS Assessment of Congenitally Deafned Children and Neonatal Deafness Screnning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

220 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-30

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the diagnostic value of NGS screnning in prelingually deafned children using a new designed chip, and to evaluate its interest in a the neonatal screening program for ddetecting congenitally deafned children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cohort Of DEafness-gene Screening

NCT06133946

Hearing Loss

ACTIVE_NOT_RECRUITING

Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators

NCT01917747

Congenital Hearing Loss

COMPLETED NA

Functional Near Infra-Red Spectroscopic Study of Central Auditory System Cortical Functional Reorganization

NCT04043910

Hearing Loss, Unilateral

TERMINATED NA

Epidemiology of Non-syndromic Dominant Deafness

NCT01150305

Hearing Impairment

COMPLETED

Evaluation of a Cohort of Congenital Deep Deafness Patients and/or With Auditory Neuropathy, Looking for DFNB9

NCT04202185

Congenital Profound Hearing Loss

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the study is to evaluate the diagnostic value of a new panel of gene in NGS study in children presenting :

1. A congenitally deafness : it is a retrospective study in children aged 0 to 17 yrs with hearing thresholds over 40 dB in the best ear using adapted audiometric assessment,
2. A suspicion of deafness in babies aged 0 to 6 months having an abnormal response after otoacoustic emissions and automated ABR assessment.

The main outcomes studied will be the finding of a pathogenic mutation (or several mutations).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Deafness Suspicion of Congenital Deafness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genetic study in retrospective and prospective groups

Genetic screening using NGS technique in a retrospective and prospective groups. No therapeutic intervention

Genetic screening. No therapeutic intervention

Intervention Type OTHER

Genetic screening using NGS technique. No therapeutic intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genetic screening. No therapeutic intervention

Genetic screening using NGS technique. No therapeutic intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Retropective study

* Age of onset of deafness between 0 and 17 years
* With a hearing loss of one or two senses with, on the ear most affected, a hearing loss more than 40 dB in mean audiometric loss in behavioural audiometry
* Availability of detailed information in Appendix 1: History, history and course of disease, associated symptoms, otoscopy data, radiology, treatments and hearing aids implemented.
* Availability of DNA samples stored in an existing collection.
* Consent to participate in the study (non-opposition) by the legal representative

* Age of the child 0 to 6 months including corrected age having had on at least one of the two ears a lack of acoustic otoemissions and a lack of response in automated PEA, and a threshold of PEA at least on one ear at more than 40 dB.
* Availability of detailed information in Appendix 2: Personal history, family history of deafness, associated symptoms, tympanometry, otoscopy data, neonatal deafness test data.
* Collection of the consent of the legal representative

Exclusion Criteria

* Child with a known cause of observed deafness (meningitis, post-surgery or drug iatrogenic, trauma, infections, tumor)
* Family not willing to participate in the study

Prospective study

· Family not willing to participate in the study

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No